文献速递前列腺癌

ATM与BRCA1/2胚系突变与前列腺癌主动监测中的分级再分类相关

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-10-08

该研究纳入两个独立队列共1211例接受主动监测的前列腺癌患者,评估DNA修复基因(BRCA1/2和ATM)胚系突变与分级再分类的关系。竞争风险分析显示,三基因 panel 突变携带者分级再分类风险增高(调整HR=1.96,95%CI 1.004-3.84,p=0.04),BRCA2突变携带者风险更高(调整HR=2.74,95%CI 1.26-5.96,p=0.01)。结论认为BRCA1/2和ATM突变状态与主动监测中的分级再分类相关。

要点

  • BRCA1/2和ATM胚系突变携带者主动监测中分级再分类风险增高。
  • BRCA2突变携带者分级再分类风险调整HR为2.74。
  • 突变携带者更具侵袭性前列腺癌可能,监测策略需个体化。

核心结论

  • BRCA1/2和ATM胚系突变状态与接受主动监测的前列腺癌患者分级再分类相关。

研究设计与样本

  • 两个独立队列的前列腺癌主动监测患者,分别来自Johns Hopkins(882例)和North Shore(329例),共1211例。
  • 对胚系DNA进行DNA修复基因测序,包括BRCA1/2和ATM三基因panel。
  • 突变致病性依据美国医学遗传学与基因组学学会(ACMG)指南定义。
  • 采用竞争风险分析评估突变携带状态与分级再分类的关联。

主要发现

  • 1211例中289例发生分级再分类;三基因panel突变携带者26例中11例发生再分类,非携带者1185例中278例发生再分类;调整HR=1.96(95%CI 1.004-3.84,p=0.04)。
  • BRCA2突变携带者11例中6例发生再分类,非携带者1200例中283例发生再分类;调整HR=2.74(95%CI 1.26-5.96,p=0.01)。
  • 三基因panel致病突变携带率在再分类者中为3.8%,未再分类者中为1.6%(p=0.04)。
  • BRCA2致病突变携带率在再分类者中为2.1%,未再分类者中为0.5%(p=0.03)。
  • BRCA2携带率在从诊断时Gleason评分(GS)3+3再分类至GS≥4+3者中为4.1%,未再分类者为0.7%(p=0.01);在再分类至GS 3+4者中为2.1%,未再分类者为0.6%(p=0.03)。

临床怎么用

  • 对接受主动监测的前列腺癌患者,可考虑检测BRCA1/2和ATM胚系突变以辅助风险评估。
  • BRCA2突变携带者接受主动监测时需更密切监测分级再分类。

局限性

  • 突变携带者数量少。
  • 研究终点为中间终点(分级再分类)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in DNA repair genes are associated with aggressive prostate cancer (PCa). OBJECTIVE: To assess whether germline mutations are associated with grade reclassification (GR) in patients undergoing active surveillance (AS). DESIGN, SETTING, AND PARTICIPANTS: Two independent cohorts of PCa patients undergoing AS; 882 and 329 patients from Johns Hopkins and North Shore, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Germline DNA was sequenced for DNA repair genes, including BRCA1/2 and ATM (three-gene panel). Pathogenicity of mutations was defined according to the American College of Medical Genetics guidelines. Association of mutation carrier status and GR was evaluated by a competing risk analysis. RESULTS AND LIMITATIONS: Of 1211, 289 patients experienced GR; 11 of 26 with mutations in a three-gene panel and 278 of 1185 noncarriers; adjusted hazard ratio (HR)=1.96 (95% confidence interval [CI]=1.004-3.84, p=0.04). Reclassification occurred in six of 11 carriers of BRCA2 mutations and 283 of 1200 noncarriers; adjusted HR=2.74 (95% CI=1.26-5.96, p=0.01). The carrier rates of pathogenic mutations in the three-gene panel, and BRCA2 alone, were significantly higher in those reclassified (3.8% and 2.1%, respectively) than in those not reclassified (1.6% and 0.5%, respectively; p=0.04 and 0.03, respectively). Carrier rates for BRCA2 were greater for those reclassified from Gleason score (GS) 3+3 at diagnosis to GS ≥4+3 (4.1% vs 0.7%, p=0.01) versus GS 3+4 (2.1% vs 0.6%; p=0.03). Results are limited by the small number of mutation carriers and an intermediate end point. CONCLUSIONS: Mutation status of BRCA1/2 and ATM is associated with GR among men undergoing AS. PATIENT SUMMARY: Men on active surveillance with inherited mutations in BRCA1/2 and ATM are more likely to harbor aggressive prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Carter HB, Helfand B, Mamawala M, et al. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol. 2018. PMID: 30309687. doi:10.1016/j.eururo.2018.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。